Cytokinetics Interest Expense vs Income Tax Expense Analysis
| CYTK Stock | USD 49.10 1.43 3.00% |
Cytokinetics financial indicator trend analysis is way more than just evaluating Cytokinetics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytokinetics is a good investment. Please check the relationship between Cytokinetics Interest Expense and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.
Interest Expense vs Income Tax Expense
Interest Expense vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytokinetics Interest Expense account and Income Tax Expense. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Cytokinetics' Interest Expense and Income Tax Expense is 0.53. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Cytokinetics, assuming nothing else is changed. The correlation between historical values of Cytokinetics' Interest Expense and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Cytokinetics are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Interest Expense i.e., Cytokinetics' Interest Expense and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | 0.53 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Income Tax Expense
Most indicators from Cytokinetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.At this time, Cytokinetics' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 24.21 this year, although Enterprise Value Multiple is projected to rise to (18.10).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 256.7M | 418.8M | 503.7M | 528.9M | Interest Expense | 29.3M | 51.2M | 57.7M | 60.6M |
Cytokinetics fundamental ratios Correlations
Click cells to compare fundamentals
Cytokinetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cytokinetics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 289.8M | 533.8M | 841.3M | 1.0B | 824.3M | 865.5M | |
| Short Long Term Debt Total | 136.1M | 138.9M | 269.9M | 749.3M | 755.8M | 793.6M | |
| Total Stockholder Equity | (10.9M) | 113.4M | 243.9M | (107.9M) | (386.3M) | (367.0M) | |
| Net Debt | 99.6M | 56.0M | 157.3M | 683.8M | 642.7M | 674.9M | |
| Retained Earnings | (865.0M) | (992.3M) | (1.2B) | (1.6B) | (2.1B) | (2.0B) | |
| Common Stock Shares Outstanding | 57.6M | 64.5M | 76.9M | 89.8M | 96.5M | 101.4M | |
| Liabilities And Stockholders Equity | 289.8M | 533.8M | 841.3M | 1.0B | 824.3M | 865.5M | |
| Non Current Liabilities Total | 274.7M | 389.2M | 525.6M | 1.0B | 1.1B | 1.2B | |
| Other Stockholder Equity | 853.3M | 1.1B | 1.5B | 1.5B | 1.7B | 1.8B | |
| Total Liab | 300.8M | 420.4M | 597.5M | 1.1B | 1.2B | 1.3B | |
| Other Current Liab | 1.1M | 17.6M | 21.0M | 33.3M | 35.3M | 37.1M | |
| Total Current Liabilities | 26.0M | 31.2M | 71.9M | 84.6M | 102.7M | 107.8M | |
| Other Liab | 143.3M | 253.1M | 270.5M | 300.5M | 345.6M | 362.9M | |
| Property Plant And Equipment Net | 13.4M | 22.6M | 146.4M | 163.2M | 147.7M | 155.1M | |
| Current Deferred Revenue | 12.1M | 19.3M | 34.4M | 12.4M | 14.2M | 12.3M | |
| Accounts Payable | 8.2M | 8.1M | 21.1M | 25.6M | 21.5M | 22.6M | |
| Cash | 36.4M | 83.0M | 112.7M | 65.6M | 113.0M | 118.7M | |
| Non Current Assets Total | 56.1M | 59.6M | 305.6M | 219.6M | 196.3M | 206.1M | |
| Non Currrent Assets Other | 8.9M | 9.3M | 7.2M | 9.7M | 8.0M | 4.0M | |
| Long Term Debt | 45.1M | 46.2M | 47.4M | 63.8M | 607.4M | 637.7M | |
| Cash And Short Term Investments | 225.1M | 464.1M | 471.6M | 782.6M | 614.8M | 645.6M | |
| Net Receivables | 5.2M | 4.4M | 51.8M | 147K | 1.3M | 1.2M | |
| Common Stock Total Equity | 59K | 70K | 84K | 94K | 108.1K | 58.5K | |
| Short Term Investments | 188.7M | 381.1M | 359.0M | 717.0M | 501.8M | 526.9M | |
| Other Current Assets | 3.5M | 5.7M | 12.2M | 12.5M | 11.9M | 12.5M | |
| Property Plant And Equipment Gross | 13.4M | 22.6M | 146.4M | 163.2M | 176.1M | 184.9M | |
| Total Current Assets | 233.8M | 474.2M | 535.7M | 795.2M | 628.1M | 659.5M | |
| Accumulated Other Comprehensive Income | 343K | 500K | 679K | (869K) | (3.6M) | (10.5K) | |
| Short Term Debt | 4.6M | 5.6M | 29.7M | 25.7M | 45.9M | 48.2M | |
| Common Stock | 59K | 70K | 84K | 94K | 102K | 96.9K | |
| Property Plant Equipment | 4.5M | 13.3M | 73.3M | 80.5M | 92.5M | 97.1M | |
| Net Tangible Assets | (10.9M) | 113.4M | 243.9M | (107.9M) | (97.1M) | (92.3M) | |
| Retained Earnings Total Equity | (865.0M) | (992.3M) | (1.2B) | (1.6B) | (1.4B) | (1.4B) | |
| Capital Surpluse | 853.3M | 1.1B | 1.5B | 1.5B | 1.7B | 921.5M | |
| Long Term Investments | 42.7M | 37.0M | 152.1M | 46.7M | 40.5M | 38.0M | |
| Long Term Debt Total | 45.1M | 46.2M | 47.4M | 63.8M | 73.4M | 43.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.